Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial
Published in: Lancet Haematology
Access to document
10.1016/S2352-3026(26)00068-2
BACKGROUND: Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [ 18F]fluorodeoxyglucose ([ 18F]FDG)-PET-guided treatment adaptation after one cycle of A-AVD improves activity while limiting exposure to intensive chemotherapy. METHODS: This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO...
Martin Hutchings, Arjan Diepstra, Anna Sureda Balari, Susana Carvalho, Andrej Vranovsky, Walter Noordzij, Annika Loft, Anne Arens, Sophie Teesink, Lydia Visser, Wendy Stevens, Berthe M P Aleman, F J Sherida H Woei-A-Jin, Maria Viguria, Kirsten Saevels, Liane Te Boome, Sanne Tonino, Paul Meijnders, Eva Domingo Domènech, Caroline Hasselbalch RileyLaure Musekera, Sarah Nuyens, Cedric Mallien, Ward Sents, Emanuel Bührer, Catherine Fortpied, Wouter J Plattel
The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors
Published in: Journal of the National Cancer Institute
Access to document
10.1093/jnci/djag080
BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of late adverse events, eg cardiovascular diseases (CVD), breast cancer (bc), hypothyroidism and severe infections. At Dutch BETER clinics, HL survivors are regularly screened for (risk factors for) these adverse events. The impact of survivorship care on burden of disease from adverse outcomes has rarely been evaluated. METHODS: In a nationwide retrospective cohort study, we compared HL survivors invited for BETER care in 2013 to 2016 (intervention group) with matched survivors who were eligible for such care, but were...
Eline Mj Lammers, Josée M Zijlstra, Michael Schaapveld, Juanita A Haagsma, Cécile Pm Janus, Karin M Aarsman, Liane Cj Te Boome, Maaike Mg Schippers, Rinske S Boersma, Saskia E Rademakers, Wouter J Plattel, Lara H Böhmer, Marieke Van Den Berg, Adriaantje C Kroeze, Leonie S Strobbe, Wendy Deenik, Heleen S De Lil, Berthe Mp Aleman, Flora E Van Leeuwen, Annelies Nijdam
Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years
Published in: Clinical lymphoma, myeloma & leukemia
Access to document
10.1016/j.clml.2025.12.007
document
BACKGROUND: High dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) remains the preferred consolidation strategy for patients with newly diagnosed multiple myeloma (MM). While its use has expanded to patients over 65 years (> 65), few studies have compared real-world outcomes to younger patients. PATIENTS AND METHODS: This retrospective cohort study included patients with MM who received first line HDT/ASCT between 2013 and 2022 at a large tertiary referral center in The Netherlands. We compared outcomes between patients > 65 years and 65 years or younger (≤...
Koen M Klomberg, Miriam Gelderloos, Hilde A M Kooistra, Marcel Nijland, Geertruida H de Bock, Gerwin A Huls, Mirian Brink, Wilfried W H Roeloffzen, Wouter J Plattel
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma
Published in: Journal of the National Cancer Institute
Access to document
10.1093/jnci/djag085
BACKGROUND: Few studies examined treatment-specific long-term risks of cardiovascular diseases (CVD) in diffuse large B-cell lymphoma (DLBCL) survivors treated with potentially cardiotoxic radiotherapy and/or chemotherapy with/without rituximab after the 1990s. METHODS: Long-term CVD risk was examined in a multicenter cohort comprising 2,356 ≥ 5-year DLBCL survivors treated at ages 15 to 61 years in 1989 to 2012. CVD data were acquired from medical records, general practitioners and disease-registries. Observed CVD-numbers were compared with expected CVD-incidence in the Dutch population to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10,000 person-years)....
Yvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, Cécile P M Janus, Augustinus D G Krol, Dick Johan van Spronsen, Wouter J Plattel, Judith M Roesink, Karijn M S Verschueren, Josée M Zijlstra, Harry R Koene, Marten R Nijziel, Erik C Schimmel, Eva de Jongh, Francisca Ong, Liane C J Te Boome, Rozemarijn S van Rijn, Lara H Böhmer, Bastiaan D P Ta, Hein P J VisserEduardus F M Posthuma, Yavuz M Bilgin, Karin Muller, Daphne van Kampen, Jan-Paul de Boer, Cynthia So-Osman, Joost S P Vermaat, Roel J de Weijer, Marie José Kersten, Flora E van Leeuwen, Yolande Appelman, Michael Schaapveld
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients
Published in: Journal of the National Cancer Institute
Access to document
10.1093/jnci/djag090
BACKGROUND: Hodgkin lymphoma (HL) patients are at increased risk of developing lung cancer (LC), especially after chest radiotherapy (RT). However, there are no tools to predict LC risk for different HL treatments. METHODS: In a cohort of 5,370 ≥ 5-year HL survivors aged 15 to 50 years at HL diagnosis and treated in the Netherlands between 1965 to 2012, we used RT fields and prescribed dose to estimate mean lung dose (MLD). The twinning method was used to divide the cohort into homogenous parts: 80% for model development and 20% for...
Shahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, Saskia E Rademakers, Judith Roesink, Maaike G A Schippers, Bastiaan D P Ta, Wouter J Plattel, Josée M Zijlstra, Dominic A X Schinagl, Marten R Nijziel, Francisca Ong, Erik C Schimmel, Eduardus F M Posthuma, Laurien A Daniels, Lara H Böhmer, Karin Muller, Harry R Koene, Liane C J Te Boome, Yavuz M BilginEva De Jongh, Cécile P M Janus, Berthe M P Aleman, Michael Schaapveld